SNC
JAZZ icon

Stifel Nicolaus & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Stifel Nicolaus & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$365K Buy
3,971
+686
+21% +$55.3K 0.01% 1051
2013
Q2 		$226K Buy
+3,285
New +$201K ﹤0.01% 1224

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

Stifel Nicolaus & Co's JAZZ Position: Q3 2013 in Review

Stifel Nicolaus & Co increased its Jazz Pharmaceuticals (JAZZ) stake by 21% in Q3 2013, buying an estimated $55.3K and bringing the position to 3,971 shares worth $365K. The position accounts for 0.01% of the portfolio, ranked #1051.

Stifel Nicolaus & Co first reported a position in JAZZ in Q2 2013 and has held it in 2 quarters since. 249 funds tracked by Wall St. Rank hold JAZZ as of Q3 2013.

  • Stifel Nicolaus & Co held 3,971 shares of Jazz Pharmaceuticals worth $365K as of Q3 2013.
  • Stifel Nicolaus & Co bought 686 Jazz Pharmaceuticals shares in Q3 2013, an estimated $55.3K.
  • Jazz Pharmaceuticals made up 0.01% of Stifel Nicolaus & Co's portfolio in Q3 2013, its #1051 holding.
  • Stifel Nicolaus & Co first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 2 quarters since.
  • 249 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.